 |
323 Products |  |
957 Diseases | | 323 Products |
|
1268 Trials |  |
64372 News |  |
| «12345678910111213...750751» |
- | Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: T3STOPBPS: Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome (clinicaltrials.gov) - Apr 19, 2024
P1, N=5, Active, not recruiting, Sponsor: Stanford University
Recruiting --> Active, not recruiting | N=12 --> 5 | Trial completion date: Sep 2024 --> Feb 2025 | Trial primary completion date: Sep 2024 --> Feb 2025
- mapatumumab (HGS-ETR1) / GSK
Phase classification, Combination therapy, Metastases: Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer (clinicaltrials.gov) - Apr 19, 2024
P1/2, N=9, Completed, Sponsor: University Medical Center Groningen
Recruiting --> Active, not recruiting | N=12 --> 5 | Trial completion date: Sep 2024 --> Feb 2025 | Trial primary completion date: Sep 2024 --> Feb 2025 Phase classification: P1b/2 --> P1/2
- || ivermectin oral / Generic mfg.
Review, Journal: COVID-19: An Update on Epidemiology, Prevention and Treatment, September-2023. (Pubmed Central) - Apr 18, 2024
At the current phase of the pandemic, nirmatrelvir/ritonavir, remdesivir, molnupiravir, sotrovimab (for patients from XBB.1.5 variant dominant settings), and convalescent plasma can be considered for the treatment of high-risk early-stage outpatients with COVID-19, while hospitalized patients with more severe disease can be treated with dexamethasone, anti cytokines including tocilizumab, sarilumab, baricitinib, and tofacitinib and antithrombotic agents including enoxaparin. Remdesivir oral analogues and ensitrelvir fumarate are promising agents for treating acute COVID-19, which are in phase trials now; however, ivermectin, fluvoxamine, and metformin were shown to be ineffective.
- |||||||||| Arexvy (respiratory syncytial virus vaccine, adjuvanted) / GSK
New P3 trial: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above (clinicaltrials.gov) - Apr 17, 2024
P3, N=850, Not yet recruiting, Sponsor: GlaxoSmithKline
- | Keytruda (pembrolizumab) / Merck (MSD), Blenrep (belantamab mafodotin-blmf) / GSK
Journal: Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma. (Pubmed Central) - Apr 17, 2024
P1/2
The results of DREAMM-4 demonstrated clinical activity and a favorable safety profile of belamaf plus pembrolizumab in patients with RRMM. This trial is registered at www.
- | Bexsero (meningococcal group B vaccine) / GSK
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness of 4CMenB vaccination against gonorrhea: importance of dosing schedule, vaccine sentiment, targeting strategy, and duration of protection. (Pubmed Central) - Apr 17, 2024
At UK costs, targeted 4CMenB vaccination of MSM gains QALYs and is cost-saving at any uptake level. Promoting uptake maximizes benefits and is an important role for behavioral science.
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal, Adherence: Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS (Pubmed Central) - Apr 17, 2024
P=N/A
Promoting uptake maximizes benefits and is an important role for behavioral science. While access to CHORUS
- | GSK2798745 / GSK
Journal: Effect of TRPV4 Antagonist GSK2798745 on Chlorine Gas-Induced Acute Lung Injury in a Swine Model. (Pubmed Central) - Apr 17, 2024
Exposure to 240 parts per million (ppm) chlorine gas for ?50 min resulted in acute lung injury characterized by sustained changes in the ratio of partial pressure of oxygen in arterial blood to the fraction of inspiratory oxygen concentration (PaO2/FiO2), oxygenation index, peak inspiratory pressure, dynamic lung compliance, and respiratory system resistance over 24 h. Chlorine exposure also heightened airway response to methacholine and increased wet-to-dry lung weight ratios at 24 h. Following 55-min chlorine gas exposure, GSK2798745 marginally improved PaO2/FiO2, but did not impact lung function, airway responsiveness, wet-to-dry lung weight ratios, airway inflammation, or histopathology. In summary, in this swine model of chlorine gas-induced acute lung injury, GSK2798745 did not demonstrate a clinically relevant improvement of key disease endpoints.
- | Benlysta (belimumab) / GSK
Journal: Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use? (Pubmed Central) - Apr 17, 2024
Our data confirm that BEL is effective in controlling disease activity, and in recent years BEL has been considered as an earlier treatment option before other IS. Early introduction of BEL can be at least as effective as a step-up approach and can help to reduce the GC dosage.
- | Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Journal: Haytox: what is the evidence for a Botox spray for hay fever? (Pubmed Central) - Apr 17, 2024
Early introduction of BEL can be at least as effective as a step-up approach and can help to reduce the GC dosage. No abstract available
- | Victoza (liraglutide) / Novo Nordisk, Xenical (orlistat) / Roche, GSK, Saxenda (liraglutide 3 mg) / Novo Nordisk
Journal: Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment. (Pubmed Central) - Apr 17, 2024
The present GL is directed to all physicians addressing people with obesity-working in hospitals, territorial services or private practice-and to general practitioners and patients. The recommendations should also consider the patient's preferences and the available resources and expertise.
- || Zejula (niraparib) / GSK, J&J
P2 data, Review, Journal, BRCA Biomarker, PARP Biomarker: Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B. (Pubmed Central) - Apr 17, 2024
The recommendations should also consider the patient's preferences and the available resources and expertise. The primary end
- | Brexafemme (ibrexafungerp) / SCYNEXIS, GSK
Retrospective data, Journal: Efficacy and safety of ibrexafungerp in the treatment of vulvovaginal candidiasis: A meta-analysis of randomized controlled trials. (Pubmed Central) - Apr 17, 2024
When ibrexafungerp was compared to fluconazole/placebo, the duration of any treatment-related treatment-emergent adverse events (TEAE), nausea, and diarrhea during therapy was significantly longer. In summary, the use of ibrexafungerp was linked to superior clinical cure ratio, and mycological eradication when compared to fluconazole/placebo.
- |||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment closed, Adverse events: A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants (clinicaltrials.gov) - Apr 17, 2024
P3, N=140, Active, not recruiting, Sponsor: AbbVie
In summary, the use of ibrexafungerp was linked to superior clinical cure ratio, and mycological eradication when compared to fluconazole/placebo. Recruiting --> Active, not recruiting
- | Nucala (mepolizumab) / GSK
Trial completion date, Trial primary completion date: Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment (clinicaltrials.gov) - Apr 17, 2024
P4, N=90, Recruiting, Sponsor: St. Paul's Sinus Centre
Recruiting --> Active, not recruiting Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jan 2024 --> Dec 2024
- | Horizant (gabapentin enacarbil XR) / Azurity Pharma, Astellas, GSK
Journal: Reductions in World Health Organization risk drinking level are associated with improvements in sleep problems among individuals with alcohol use disorder. (Pubmed Central) - Apr 16, 2024
Drinking reductions, including those short of abstinence, are associated with improvements in sleep problems during treatment for AUD. Additional assessment of the causal relationships between harm-reduction approaches to AUD and improvements in sleep is warranted.
- | gepotidacin (GSK2140944) / GSK
Journal: Interactions between Gepotidacin and Escherichia coli Gyrase and Topoisomerase IV: Genetic and Biochemical Evidence for Well-Balanced Dual-Targeting. (Pubmed Central) - Apr 16, 2024
Mutations in GyrA and ParC amino acid residues that interact with gepotidacin altered the activity of the compound against the enzymes and, when present in both gyrase and topoisomerase IV, reduced the antibacterial activity of gepotidacin against this mutant strain. Our studies provide insights regarding the well-balanced dual-targeting of gyrase and topoisomerase IV by gepotidacin in E. coli.
- | Tavegil (clemastine) / GSK
Journal: Development of Eco-Friendly Scattering and Fluorimetric Methods for the Determination of Clemastine Through Its Interaction with Eosin Y: Assessment of Whiteness, Blueness, and Greenness Tools. (Pubmed Central) - Apr 16, 2024
Furthermore, analytical Eco scale and comprehensive assessments of whiteness, blueness, and greenness were carried out utilizing Modified NEMI, ComplexGAPI, and AGREE evaluation tools. Additionally, recently developed tools such as BAGI and RGB 12 were applied to assess the blueness and the whiteness of the suggested methods.
- | Inavir (laninamivir) / Daiichi Sankyo, Rapivab (peramivir) / BioCryst, Relenza (zanamivir) / GSK, Vaxart
Preclinical, Journal: Synthesis of Rupestonic Acid L-Ephedrine Derivatives with Preliminary In vitro Anti-influenza Viral Activity. (Pubmed Central) - Apr 16, 2024
Compound A can be regarded as a very promising lead compound for the development of anti-influenza inhibitors. Based on these results, more rupestonic acid derivatives will be designed and synthesized in the future for the development of anti-influenza inhibitors.
- | Nucala (mepolizumab) / GSK
Journal: Exploring novel perspectives on eosinophilic inflammation in severe asthma. (Pubmed Central) - Apr 16, 2024
Moreover, CD62Llow iEos were reduced after treatment with the anti-IL-5 monoclonal antibody mepolizumab. In the future, we believe that eosinophil subtypes could represent a useful biomarker in severe eosinophilic asthma, helping clinicians characterize patient endotypes and monitoring the response to biological drugs.
- || Ojjaara (momelotinib) / GSK
Review, Journal: Momelotinib in myelofibrosis. (Pubmed Central) - Apr 16, 2024
Due to its mechanism of action, MMB represents a valuable therapeutic option in MF, addressing the clinical challenge of anemia and potentially improving outcomes for patients with hematologic malignancies. Ongoing research explores MMB's potential in acute myeloid leukemia and combination therapies.
- | Prolia (denosumab) / Amgen
Journal: On-time denosumab dosing recovered rapidly during the COVID-19 pandemic, yet remains suboptimal. (Pubmed Central) - Apr 16, 2024
Although on-time dosing remains stable as of February 2022, approximately one-fourth of patients in the community do not receive denosumab on-time. In conclusion, although pandemic disruptions to denosumab dosing were temporary, levels of on-time therapy remain suboptimal.
- | Nucala (mepolizumab) / GSK
Trial termination: Mepolizumab in Episodic Angioedema With Eosinophilia (clinicaltrials.gov) - Apr 16, 2024
P2, N=5, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
In conclusion, although pandemic disruptions to denosumab dosing were temporary, levels of on-time therapy remain suboptimal. Completed --> Terminated; Study was closed after the first five participants completed their participation due to lack of efficacy.
- |||||| lisaftoclax (APG-2575) / Ascentage Pharma
Enrollment open, Combination therapy: A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. (clinicaltrials.gov) - Apr 16, 2024
P3, N=344, Recruiting, Sponsor: Ascentage Pharma Group Inc.
Completed --> Terminated; Study was closed after the first five participants completed their participation due to lack of efficacy. Not yet recruiting --> Recruiting
- | Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Journal: Risk factors and early preventive measures for long COVID in non-hospitalized patients: analysis of a large cohort in the United Arab Emirates. (Pubmed Central) - Apr 16, 2024
Not yet recruiting --> Recruiting This study contributes to the existing knowledge by identifying risk factors for long COVID among non-hospitalized patients and emphasizing the potential benefits of pre-COVID vaccination and timely treatment.
- || Review, Journal: The interplay of rheumatoid arthritis and osteoporosis: exploring the pathogenesis and pharmacological approaches. (Pubmed Central) - Apr 16, 2024
This review will shed light on the relationship between osteoporosis and rheumatoid arthritis as well as the various factors that influence the onset of osteoporosis in RA patients. We also explore several treatment approaches to effectively managing osteoporosis in RA patients.
- | Prolia (denosumab) / Amgen
Journal: Recognizing bisphosphonate-induced ear osteonecrosis in primary care: a case report. (Pubmed Central) - Apr 16, 2024
Unexplained ear symptoms in those with a history of current or prior anti-resorptive therapy should raise clinical concern, prompting evaluation for exposed bone in the EAC. Raising awareness of MRECO among primary care providers is crucial for early diagnosis and timely management.
- || VH4011499 / GSK, ViiV Healthcare
New P1 trial: A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants (clinicaltrials.gov) - Apr 16, 2024
P1, N=36, Not yet recruiting, Sponsor: ViiV Healthcare
- | mammaglobin-A DNA vaccine / Washington University School of Medicine in St. Louis
Phase classification: Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov) - Apr 16, 2024
P1, N=27, Active, not recruiting, Sponsor: Washington University School of Medicine
Raising awareness of MRECO among primary care providers is crucial for early diagnosis and timely management. Phase classification: P1b --> P1
- | Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, COMIRNATY Original/Omicron BA.4-5 (tozinameran/famtozinameran) / Pfizer, BioNTech, Vidprevtyn (GSK4353001A) / Sanofi, GSK
Journal: Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation in England. (Pubmed Central) - Apr 15, 2024
The finding that the adjuvanted vaccine targeting the distant Beta strain had similar effectiveness to the bivalent mRNA vaccine targeting more closely matched Omicron sub-lineages is notable and highlights the need for further real-world studies into the effectiveness of vaccines from different vaccine platforms and formulations in the presence of matched and unmatched strains. No external funding.
- | Benlysta (belimumab) / GSK
Journal: Fetal hemophagocytic lymphohistiocytosis with intravascular large B-cell lymphoma following coronavirus disease 2019 vaccination in a patient with systemic lupus erythematosus: an intertwined case. (Pubmed Central) - Apr 15, 2024
We report a case of neuropsychiatric symptoms and refractory HLH in a woman with systemic lupus erythematosus (SLE) after receiving her COVID-19 vaccine treated with belimumab, later found to have intravascular large B-cell lymphoma (IVLBCL) at autopsy...The patient was diagnosed with HLH and treated with etoposide, dexamethasone and cyclosporine...Differentiating comorbid conditions remains difficult; however, in the case of an atypical clinical presentation, other causes should be considered. Therefore, we speculate that the COVID-19 vaccination and her autoimmune condition may have expedited IVLBCL development.
- ||| Journal, Adverse events: Association between CDK4/6 inhibitors and drug-related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System. (Pubmed Central) - Apr 15, 2024
A signal was detected even after adjusting for sex, age, and concomitant medications as covariates (aROR0025: 5.74)...To the best of our knowledge, this is the first report on CDK4/6 inhibitors and drug-related osteonecrosis of the jaw. We believe that these results will offer new insights into adverse events related to the use of CDK4/6 inhibitors, and may aid in the proper use of CDK4/6 inhibitors.
- | Prolia (denosumab) / Amgen
Journal: Evaluating the comparability of osteoporosis treatments using propensity score and negative control outcome methods in UK and Denmark electronic health record databases. (Pubmed Central) - Apr 15, 2024
This study assessed the comparability of denosumab vs oral bisphosphonate (OBP) groups using propensity score (PS) methods and negative control outcome (NCO) analysis...Within DNR, no NCOs had HR estimates with upper or lower CI limits beyond the specified bounds indicating residual confounding for any PS method. Achievement of covariate balance and determination of residual bias were dependent upon several factors including the population under study, PS method, prevalence of NCO, and the threshold indicating residual confounding.
- | Prolia (denosumab) / Amgen
Journal, HEOR, Cost-effectiveness, Cost effectiveness: The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis. (Pubmed Central) - Apr 15, 2024
The utilization of lower cost osteoporosis medications such as oral bisphosphonates and estrogen hormonal therapy as PPF prophylaxis in this patient population would be economically viable if they reduce the PPF rate by 1.8% and 1.5%, respectively. For IV bisphosphonates and newer agents to be economically viable as PPF prophylaxis in the USA, their costs need to be significantly reduced.
- | Tabrecta (capmatinib) / Incyte, Novartis, GSK1521498 / GSK, lifirafenib (BGB-283) / BeiGene
Journal, Gene Signature: T cell-mediated tumor killing sensitivity gene signature-based prognostic score for acute myeloid leukemia. (Pubmed Central) - Apr 15, 2024
A T-cell mediated killing sensitivity gene-based prognostic score TTKPI showed good accuracy in predicting survival in AML. TTKPI corresponded to functional and immunological features of the tumor microenvironment including checkpoint expression patterns and should be investigated for precision medicine approaches.
- | Journal: A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells. (Pubmed Central) - Apr 15, 2024
Through this work, we identified repurposed candidate therapeutics against GBM utilizing a GSC inclusive targeting approach, which demonstrated high in vitro efficacy and can prospectively evade drug resistance. These drugs have the potential to be developed as individual or combination therapy to improve GBM outcomes.
- || Jesduvroq (daprodustat) / GSK, Kyowa Kirin
Review, Journal: Daprodustat: A Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease. (Pubmed Central) - Apr 15, 2024
It was Food and Drug Administration approved in 2023 in patients already receiving dialysis for at least 4 months but not in non-dialysis patients. Long-term data for safety and additional benefits are pending.
- || Cosentyx (secukinumab) / Novartis
Review, Journal: Membranous lupus nephritis secondary to secukinumab therapy: A case report and literature review. (Pubmed Central) - Apr 15, 2024
Secukinumab was discontinued, while tacrolimus was initiated, subsequently switched to cyclosporin, belimumab, glucocorticosteroid, and hydroxychloroquine with a good response. The relationship between lupus erythematosus and IL-17 inhibition requires further research.
- || gepotidacin (GSK2140944) / GSK, zoliflodacin (ETX0914) / Entasis Therap, Global Antibiotic Research and Development Partnership
Review, Journal: Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance. (Pubmed Central) - Apr 15, 2024
Phase III clinical trials that utilized two members of these classes, gepotidacin (triazaacenaphthylene) and zoliflodacin (spiropyrimidinetrione), have been completed with positive outcomes, underscoring the potential of these compounds to become the first new classes of antibacterials introduced into the clinic in decades. Because gyrase and topoisomerase IV are validated targets for established and emerging antibacterials, this review will describe the catalytic mechanism and cellular activities of the bacterial type II topoisomerases, their interactions with fluoroquinolones, the mechanism of target-mediated fluoroquinolone resistance, and the actions of novel antibacterials against wild-type and fluoroquinolone-resistant gyrase and topoisomerase IV.
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Journal: Herombopag for the treatment of persistent thrombocytopenia following hematopoietic stem cell transplantation. (Pubmed Central) - Apr 15, 2024
Twelve patients survived and six patients died, with an overall survival rate of 66.7%. This is the first study to demonstrate the efficacy and safety of herombopag in transplantation-associated thrombocytopenia after failing eltrombopag, introducing a new approach in the treatment of PT following allo-HSCT.
- | Benlysta (belimumab) / GSK
Retrospective data, Journal: The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study. (Pubmed Central) - Apr 15, 2024
Further studies are needed to validate these findings in larger patient populations and compare the efficacy of belimumab with other treatments for SLE complicated with ITP. Long-term response rates and adverse events associated with belimumab treatment also warrant further investigation.
- | Benlysta (belimumab) / GSK
Retrospective data, Journal: Initiation of belimumab with higher daily prednisolone is effective for rapid glucocorticoid reduction: A 96-week retrospective study. (Pubmed Central) - Apr 15, 2024
Long-term response rates and adverse events associated with belimumab treatment also warrant further investigation. Our study showed that a delay in belimumab initiation led to higher SLEDAI-2K score and difficulty in achieving a 50% GC reduction at 96
- | Zejula (niraparib) / GSK, J&J
Journal, Metastases: A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. (Pubmed Central) - Apr 15, 2024
P1
Niraparib tablets were found to be bioequivalent to capsules. A modest (?32%) FE was observed with a high-fat meal, but was not considered to be clinically meaningful, given niraparib's PK variability.
- || Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono
Review, Journal: Pregnancy and breastfeeding in women with multiple sclerosis (Pubmed Central) - Apr 15, 2024
A modest (?32%) FE was observed with a high-fat meal, but was not considered to be clinically meaningful, given niraparib's PK variability. For highly active courses of the disease, anti-CD20 antibodies, cladribine, or continued administration of natalizumab show the best data...If women have had a
- | Anoro Ellipta (umeclidinium/vilanterol) / Innoviva, GSK, Ultibro (glycopyrronium/indacaterol) / Novartis
Journal: Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020-2023. (Pubmed Central) - Apr 15, 2024
However, these results do not prove that LAMAs cause CV AEs, as FAERS data alone are not indicative of a drug's safety profile. Given the frequency with which COPD and cardiovascular disease co-exist, a large study in the general population could shed light on this very important issue.
- || Jemperli (dostarlimab-gxly) / GSK, Zejula (niraparib) / GSK, J&J
New P2 trial: Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers (clinicaltrials.gov) - Apr 15, 2024
P2, N=20, Not yet recruiting, Sponsor: Ibrahim Halil Sahin
- | Dupixent (dupilumab) / Sanofi, Regeneron, Nucala (mepolizumab) / GSK, Xolair (omalizumab) / Roche, Novartis
Biomarker, Trial completion date, Trial primary completion date: NASUMAB: Real Life Study of Biologicals in Patients With Severe CRSwNP (clinicaltrials.gov) - Apr 14, 2024
P=N/A, N=180, Recruiting, Sponsor: University Hospital, Ghent
Given the frequency with which COPD and cardiovascular disease co-exist, a large study in the general population could shed light on this very important issue. Trial completion date: Sep 2024 --> Dec 2030 | Trial primary completion date: Dec 2023 --> Dec 2030
- Prolia (denosumab) / Amgen
The Effectiveness of Bisphosphonates on Recurrent Osteoporotic Fractures Post-Denosumab Discontinuation Using Causal Machine Learning () - Apr 14, 2024 - Abstract #ISPOR2024ISPOR_2549;
Moreover, it highlights the potential of employing causal machine learning in health-related outcomes research, introducing a novel methodology for evaluating treatment effects in clinical practice. However, further research is essential to generalize these clinical and methodological findings.
- | GW842166 / GSK
Preclinical, Journal: A mouse model of chronic primary pain that integrates clinically relevant genetic vulnerability, stress, and minor injury. (Pubmed Central) - Apr 14, 2024
Yet, pain in the CPPC model was alleviated by the beta-3 adrenergic antagonist SR59230A. Thus, the CPPC mouse model reliably recapitulates clinically and biologically relevant features of CPPCs and may be implemented to test underlying mechanisms and find new therapeutics.
- | Preclinical, Journal: The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction. (Pubmed Central) - Apr 13, 2024
Renal EPO induction is the major target of HIF-PH inhibitors for their therapeutic effects on erythropoiesis. Additionally, the drug-specific properties of HIF-PH inhibitors in EPO induction and iron metabolism have been shown in mice, providing useful information for selecting the proper HIF-PH inhibitor for each renal anemia patient.